Pomalidomide for Cough in Patients With Idiopathic Pulmonary Fibrosis
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and efficacy of pomalidomide over a 12
week duration in the treatment of chronic cough in patients with IPF as measured by a Cough
Symptom Diary, Visual Analogue Scale for Cough Severity, Leicester Cough Questionnaire, St.
George Respiratory Questionnaire, Cough-Specific Quality-of-Life Questionnaire, and adverse
event reporting. There will be an option open to participants, who respond to treatment by
meeting pre-determined criteria, to remain in the study for an additional 9 months or for a
total of 54 weeks.